Rifampicin adsorption and release study using Santa Barbara amorphous-16 modified Al (SBA-16-Al) for a drug delivery system

使用 Santa Barbara 无定形-16 改性 Al (SBA-16-Al) 作为药物输送系统的利福平吸附和释放研究

阅读:16
作者:Maria Christina Prihatiningsih, Chaidir Pratama, Noor Anis Kundari, Kartini Megasari, Dhita Ariyanti, Andri Saputra, Hersandy Dayu Kusuma, Puji Astuti

Abstract

In this study, the surface modification of Santa Barbara Amorphous-16 (SBA-16) with aluminum (SBA-16-Al) was carried out as a rifampicin matrix for the treatment of tuberculosis. Surface modification of SBA-16 was achieved using the direct-synthesis grafting method. Then, the adsorption and release properties of rifampicin from the SBA-16-Al matrix have been studied in batches. In addition, the SBA-16-Al has been characterized using Fourier-Transform Infrared Spectroscopy (FTIR), X-ray diffraction analysis (XRD), transmission electron microscopy (TEM), and Surface Area Analysis (SAA) Brunaur, Emmett and Teller (SAA-BET). The results show that the mesoporous material, the SBA-16-Al has a specific surface area of 843.5 m2 g-1 and 624.3 m2 g-1 for SBA-16, nanometer-sized pore diameters, and an amorphous crystal lattice. The FTIR spectra showed the Al-O bond at 802 cm-1 which indicates the Al group has been successfully added into SBA-16. The adsorption isotherm of rifampicin in SBA-16-Al follows the Freundlich model which illustrates the adsorption is heterogeneous and forms a multilayer. The adsorption of rifampicin is chemisorption which occurs non-spontaneously and is quite stable. The release kinetics of rifampicin in the drug delivery system followed the Higuchi model with k1 0.5472 mg 0.5/hour pH 1.5 and k2 mg 0.5/hour pH 6.5.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。